Merck (MRK) Raises Quarterly Dividend 5.5% to $0.77; 3.1% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Merck (MRK) STRIDE-3 Trial of V116 Vaccine Demonstrated Superior Immunogenicity vs PCV20 in Older Adults
November 28, 2023 6:48 AM ESTMerck (NYSE: MRK) announced results from STRIDE-3, a Phase 3 trial evaluating V116, the companys investigational 21-valent pneumococcal conjugate vaccine specifically designed to protect adults. The trial evaluated the immunogenicity, tolerability and safety of V116 compared to PCV20 (pneumococcal 20-valent conjugate vaccine) in adults who had not previously received a pneumococcal vaccine.
Results from the studys primary objectives include:
In adults 50 years of age and older (Cohort 1), V116 elicited non-inferior immune responses compared to PCV20 for all 10 serotypes common to both vaccines as measured by serotype-specific opsonophagocytic activity... More